scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.BIOPSYCH.2006.07.017 |
P698 | PubMed publication ID | 17123473 |
P50 | author | Steven P Hamilton | Q37651153 |
Patrick Mcgrath | Q42887689 | ||
Susan L Slager | Q92530010 | ||
P2093 | author name string | Eric J Peters | |
Greg D Jenkins | |||
Jeffrey B Kraft | |||
Megan S Reinalda | |||
P2860 | cites work | Why most published research findings are false | Q21092395 |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | serotonin | Q167934 |
P304 | page(s) | 734-742 | |
P577 | publication date | 2006-11-21 | |
P1433 | published in | Biological Psychiatry | Q4914961 |
P1476 | title | Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample | |
P478 | volume | 61 |
Q34347951 | A genome-wide association study of a sustained pattern of antidepressant response |
Q24656746 | A genomewide association study of citalopram response in major depressive disorder |
Q26799814 | Advances in Medications and Tailoring Treatment for Alcohol Use Disorder |
Q43145180 | An improved in silico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes |
Q47744358 | Association of 5-HTTLPR Polymorphism with the Nursing Diagnoses and the Achievement of Nursing Outcomes in Patients with Major Depression |
Q33913645 | Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder |
Q36018468 | Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study |
Q34247513 | Biomarkers to predict antidepressant response |
Q47555879 | Blood-based biomarkers predicting response to antidepressants. |
Q37998561 | CB1 receptor antagonists: new discoveries leading to new perspectives |
Q34954026 | CYP2C19 variation and citalopram response |
Q37255370 | Clinical implications of genetic variation in the serotonin transporter promoter region: a review |
Q38154911 | Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy |
Q41370271 | Comparative validity of the Adult Attachment Interview and the Adult Attachment Projective |
Q51892037 | Drug development in neuropsychopharmacology. |
Q37625437 | Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. |
Q37110720 | Epigenetic marks as the link between environment and development: examination of the associations between attachment, socioeconomic status, and methylation of the SLC6A4 gene |
Q35658177 | Estradiol and progesterone modify the effects of the serotonin reuptake transporter polymorphism on serotonergic responsivity to citalopram |
Q24632901 | Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains |
Q34590507 | Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines |
Q27015830 | From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment |
Q36103263 | Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model(1,2) |
Q28543005 | Genetic prediction of antidepressant drug response and nonresponse in Korean patients |
Q35124115 | Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. |
Q37201376 | Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health's Collaborative Center for Genomic Studies |
Q34555598 | Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics |
Q44045526 | How can we realize the promise of personalized antidepressant medicines? |
Q36367301 | Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. |
Q37108126 | Incomplete coverage of candidate genes: a poorly considered bias |
Q50082143 | Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy. |
Q49122438 | Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? |
Q35492023 | Life stressors and 5-HTTLPR interaction in relation to midpregnancy depressive symptoms among African-American women |
Q45996939 | Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. |
Q48093274 | PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder |
Q38657429 | Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks |
Q38103882 | Pharmacogenetic considerations for late life depression therapy |
Q37681573 | Pharmacogenetic considerations in the treatment of psychiatric disorders |
Q38121519 | Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research |
Q35026088 | Pharmacogenetics of antidepressants |
Q38139479 | Pharmacogenetics of mood disorders: what clinicians need to know |
Q37329171 | Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety |
Q37178537 | Pharmacogenetics studies in STAR*D: strengths, limitations, and results |
Q37791156 | Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry |
Q37205961 | Pharmacogenomics with antidepressants in the STAR*D study |
Q33326612 | Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample |
Q42378554 | Polymorphic Variations in 5-HT2A, 5-HTT and DISC 1 in First Episode Schizophrenia Patients |
Q48588111 | Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms. |
Q35237042 | Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. |
Q47666907 | Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years |
Q49047575 | Psychopharmacology: A house divided |
Q33960777 | Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response |
Q37206381 | Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression |
Q48086902 | Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life |
Q37139300 | SLC6A4 variation and citalopram response |
Q37437784 | SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. |
Q30482466 | Serotonergic function, two-mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression |
Q48048080 | Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients |
Q37114969 | Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion |
Q36491587 | Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients |
Q37445743 | Serotonin transporter polymorphism is associated with increased apnea-hypopnea index in older adults |
Q37486207 | Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression |
Q33318080 | Serotonin, inhibition, and negative mood |
Q37911004 | Surrogate markers of treatment outcome in major depressive disorder |
Q64249357 | Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk |
Q48005756 | The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression |
Q51846528 | The Promise and Reality of Pharmacogenetics in Psychiatry |
Q92453423 | The genetics of bipolar disorder |
Q34663662 | The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis |
Q35226451 | The promise and reality of pharmacogenetics in psychiatry |
Q37035245 | The serotonin transporter gene and effectiveness of SSRIs. |
Q42682469 | The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks |
Q37119173 | Translating biomarkers to clinical practice |
Q47743048 | Translational Functional Neuroimaging in the Explanation of Depression |
Q46878572 | Variants in PDE11A and PDE1A are not associated with citalopram response |
Search more.